More News Online Sources 19 Jan 2026 views ( )

Fresenius Kabi China Named Top Employer in China for Fourth Consecutive Year

Fresenius Kabi, a leading global provider of high-quality medicines and medical technologies and a key member of the Fresenius Group, today announced it has once again been certified as a 2026 Top Employer in China. This recognition reaffirms the company’s steadfast commitment to fostering employee development and building an exceptional workplace in China. In 2026, Fresenius Kabi earned the Top Employer certification in 13 countries and two regions globally—a continuation of its consistent success since 2023, when it first began receiving this prestigious acknowledgment across multiple markets.

This milestone marks a significant step forward in the company’s journey to create a world-class workplace—one that lays a solid foundation for both employees’ current growth and long-term success. Beyond celebrating past achievements, the certification serves as a powerful catalyst for advancing the #FutureFresenius strategy. It reinforces Fresenius Kabi’s ambition to be the employer of choice and underscores its people-first philosophy, ensuring employees remain at the heart of the company’s success and future growth.

Top Employers Institute is a globally recognized authority in HR certification, benchmarking, and consulting. Its certification is based on rigorous research into HR best practices across six key areas: Talent Strategy, Work Environment, Talent Acquisition, Learning & Development, Diversity & Inclusion, and Employee Well-being. In 2025, the program certified nearly 2,500 organizations across 131 countries and territories, positively impacting more than 14 million employees worldwide.

In this year’s evaluation, Fresenius Kabi China demonstrated outstanding performance across all assessed dimensions. The results reflect the company’s ongoing dedication to cultivating a workplace that supports employee growth, values individual contributions, and empowers people to reach their full potential.

Notably, the company achieved the highest assessment standards in several foundational pillars critical to building an organization where employees truly thrive. These include Employee Listening, Digital HR, Organization & Change, Learning & Development, and Talent Attraction—collectively demonstrating Fresenius Kabi’s sustained efforts to foster an empowering, engaging, and future-ready work environment.

“Being recognized as a Top Employer means we must always start with the end in mind,” said Yang Weiping, Chairman and President of Fresenius Kabi China. “At Fresenius Kabi China, we put people first—continuously optimizing career pathways, implementing global best practices to drive operational excellence, and constantly improving our workplace to support employee growth and well-being. Together, these efforts enable us to fulfill our enduring commitment: Committed to Life.”

“The 2026 Top Employer certification in China highlights Fresenius Kabi’s clear determination to build an exceptional workplace that fuels sustainable business success,” said Adrian Seligman, CEO of the Top Employers Institute. “Its talent strategy is tightly aligned with organizational goals, and its continuous drive for improvement exemplifies the transformative impact of forward-thinking HR practices. We are honored to recognize Fresenius Kabi for its outstanding contribution to creating a better world of work in China.”

About Fresenius Kabi

As a global healthcare company, Fresenius Kabi is guided by its unwavering promise—Committed to Life—to deliver innovative medicines, advanced technologies, and specialized care for patients with critical and chronic conditions. With over 41,000 employees in more than 100 countries, the company leverages its extensive product portfolio and world-class manufacturing capabilities to provide high-quality pharmaceuticals and cutting-edge medical technology solutions worldwide.

In biopharmaceuticals, Fresenius Kabi focuses on biosimilars for autoimmune diseases and oncology. As a market leader in clinical nutrition, it offers comprehensive enteral and parenteral nutrition products that significantly improve patient outcomes. In medical technology, its portfolio—including infusion pumps, cell and gene therapy equipment, and single-use devices—provides reliable life-support solutions. Additionally, as a global leader in blood collection systems, the company supplies blood banks and healthcare institutions worldwide with essential products and expertise. Its range of generic injectables and liquid formulations for infusion therapy is widely used in emergency medicine, surgery, oncology, and intensive care—saving millions of lives each year.

Rooted in a holistic approach to healthcare, Fresenius Kabi seamlessly integrates decades of experience, specialized expertise, innovation, and dedication to benefit approximately 450 million patients annually. As a vital pillar of the #FutureFresenius strategy, the company continues to advance R&D, production, and commercialization of innovative products and technologies—strengthening its position as a global leader in therapeutic solutions, elevating patient care, creating sustainable value for stakeholders, and shaping the future of healthcare.

Source: Fresenius Kabi China